Medicaid Reform And Rebates: State “Opt-Out” Proposed At Hearing
Medicaid rebates have been a fact of life in the pharmaceutical industry for 25 years. But the Affordable Care Act repeal-and-replace debate may open up the possibility of eliminating the mandatory rebates – and the requirement that all drugs be covered by the program.
You may also be interested in...
Medicaid Block Grants: Allowing More State Flexibility To Limit Rx Coverage?
Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.
Part Of The Solution? PBMs See Opportunities In Medicaid Reform
Amidst a growing chorus of criticism that pharmacy benefit managers are contributing to the problem of high drug costs, PCMA’s Merritt defends the PBM business model and points to its potential for better managing costs in Medicaid.
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.